The dual epidemic of obesity and type 2 diabetes represents one of the most pressing public health challenges of the 21st century. In the United States alone, more than 37 million people have diabetes, and approximately 90 percent of those with type 2 diabetes are overweight or have obesity. This overlap is not coincidental: excess body weight is a primary driver of insulin resistance, chronic inflammation, and metabolic dysfunction. Until recently, treatment options that effectively addressed both conditions remained limited. That changed in 2021 with the approval of Wegovy for chronic weight management, and more recently with its expanded regulatory approval for use in patients with diabetes-related obesity. This article examines the science behind Wegovy, the rigorous regulatory process that led to its expanded indication, and what these developments mean for patients and providers.

Understanding Wegovy and Its Active Ingredient, Semaglutide

Wegovy is a brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a naturally occurring incretin hormone that is released from the intestines after eating. It stimulates insulin secretion in a glucose-dependent manner, slows gastric emptying, and suppresses glucagon release. These actions help regulate blood sugar levels and reduce appetite. Unlike some earlier GLP-1 receptor agonists that required twice-daily injections, semaglutide is a long-acting formulation that can be administered once weekly.

The development of semaglutide for weight management was a deliberate extension of its proven glucose-lowering effects. The original approval of Wegovy in June 2021 by the U.S. Food and Drug Administration (FDA) was specifically for chronic weight management in adults with obesity (body mass index [BMI] of 30 kg/m² or greater) or overweight (BMI of 27 kg/m² or greater) with at least one weight-related condition such as hypertension or dyslipidemia. This initial approval was based on the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program, which demonstrated substantial weight loss—an average of 14.9 percent of baseline body weight over 68 weeks—when combined with lifestyle intervention.

However, because the original trials excluded patients with type 2 diabetes or included only a small subset, questions remained about the drug’s efficacy and safety in the diabetes population. The subsequent STEP 2 trial and other dedicated studies specifically examined semaglutide in individuals with type 2 diabetes and overweight or obesity. The results were compelling enough to prompt regulatory agencies to consider expanding the indication.

The Regulatory Path for Expanding Wegovy's Indication

Regulatory approval for a new indication requires robust evidence that the drug is both safe and effective for the proposed patient population. For Wegovy, the expanded indication for diabetes-related obesity required the submission of data from multiple phase 3 clinical trials that focused exclusively on patients with type 2 diabetes and a BMI of 27 kg/m² or greater. The FDA, along with the European Medicines Agency (EMA) and other international regulators, reviewed these data packages before granting approval.

Key Clinical Trials Supporting the Expanded Approval

The most pivotal study was the STEP 2 trial, a 68-week, randomized, double-blind, placebo-controlled trial involving 1,210 adults with type 2 diabetes and overweight or obesity. Participants received once-weekly subcutaneous semaglutide at doses of 2.4 mg (the Wegovy dose), 1.0 mg, or placebo, all in combination with lifestyle intervention. Results published in The Lancet showed that the Wegovy 2.4 mg group achieved an average weight loss of 9.6 percent, compared with 3.4 percent for placebo. Additionally, 69 percent of patients on the 2.4 mg dose lost at least 5 percent of their body weight, versus 28 percent with placebo. Glycemic control improved substantially: mean HbA1c dropped by 1.6 percentage points from a baseline of 8.0 percent, compared with 0.1 percentage points with placebo.

Another important study was the SURPASS-2 trial, which directly compared semaglutide 2.4 mg (Wegovy) with tirzepatide (Mounjaro), though tirzepatide is not yet approved for weight management in diabetes at the time of Wegovy’s expanded approval. The SURPASS program, focused on tirzepatide, provided additional context on the landscape of GLP-1–based therapies. Nevertheless, the STEP program remained the cornerstone of Wegovy’s diabetes-related obesity dossier.

Safety data from these trials showed a side-effect profile consistent with the GLP-1 class: nausea, vomiting, diarrhea, constipation, and abdominal pain were common, particularly during dose escalation. Serious adverse events included acute pancreatitis, gallbladder disease, and rare cases of diabetic retinopathy complications. The FDA required a boxed warning regarding the risk of thyroid C-cell tumors, based on rodent studies, which is standard for GLP-1 receptor agonists.

Regulatory Decisions: FDA, EMA, and Other Agencies

In the United States, the FDA approved the expanded indication for Wegovy in December 2022. The official labeling now states that Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with type 2 diabetes and a BMI of 27 kg/m² or greater. This aligns with the American Diabetes Association’s (ADA) Standards of Medical Care, which recommend considering pharmacotherapy for weight management in patients with type 2 diabetes and a BMI of 27 kg/m² or greater.

The EMA followed with a similar approval in early 2023, and regulatory bodies in Canada, Australia, and the United Kingdom have since updated their guidance. The approval process also required label updates to reflect the specific efficacy and safety data in the diabetes subgroup, including recommendations for dose titration, contraindications in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and warnings about the risk of hypoglycemia when used with insulin or sulfonylureas.

Implications for Clinical Practice

The expanded approval of Wegovy for diabetes-related obesity provides clinicians with a powerful new tool for managing the intertwined conditions. Historically, weight loss in patients with type 2 diabetes was often difficult to achieve and sustain. While metformin, SGLT2 inhibitors, and certain GLP-1 medications (such as liraglutide at the 3.0 mg dose for weight management) offered some benefit, none produced the degree of weight loss seen with semaglutide 2.4 mg. The ability to achieve an average weight loss of 9–10 percent—and in many cases greater than 15 percent—is transformative, as intentional weight loss of this magnitude can lead to diabetes remission, reduced cardiovascular risk, and improved quality of life.

Patient Selection and Candidacy

Not every patient with type 2 diabetes and obesity is an appropriate candidate for Wegovy. The label stipulates use in those with a BMI of 27 kg/m² or greater, but clinicians should also consider factors such as motivation, willingness to adhere to a daily injection and lifestyle program, and the absence of contraindications. Pregnancy, a history of pancreatitis, and severe gastrointestinal disease (such as gastroparesis) are relative or absolute contraindications. Additionally, patients with a history of diabetic retinopathy should be monitored closely, as rapid improvement in glycemic control can transiently worsen retinopathy.

Integrating Wegovy into Diabetes Care

The ADA recommends a stepwise approach to pharmacotherapy for type 2 diabetes, with metformin as first-line therapy. For patients who need additional glycemic control and weight loss, a GLP-1 receptor agonist with proven weight benefit (such as semaglutide 2.4 mg) is now an evidence-based option. Clinicians should consider starting with a lower dose of semaglutide (e.g., Ozempic at 0.5 mg or 1.0 mg) and titrating up to the 2.4 mg Wegovy dose if tolerated. However, because Ozempic is indicated specifically for glycemic control and not weight management, the Wegovy formulation with its higher dose and separate indication is the preferred choice for weight-focused therapy.

Coordination with a registered dietitian and a structured lifestyle program is essential to maximize results. The STEP 2 trial included intensive behavioral counseling: participants received 30 sessions of individual or group counseling over 68 weeks. In real-world settings, access to such resources may be limited, but clinicians can still provide basic dietary guidance and refer patients to commercial or community-based programs.

Insurance Coverage and Access

Access to Wegovy has been a significant barrier since its initial weight management approval. Insurance coverage is often restricted to patients who meet specific BMI cutoffs, have at least one weight-related comorbidity, and have tried lifestyle interventions. For the diabetes-related obesity indication, coverage may be more favorable because the drug is being used to manage a chronic disease. However, Medicare Part D plans are still prohibited from covering drugs solely for weight loss; while the expanded indication may change classification, it remains important for providers to verify coverage and consider prior authorization requirements.

The list price of Wegovy exceeds $1,300 per month without insurance. Patient assistance programs and manufacturer savings cards can reduce out-of-pocket costs for eligible individuals. Prescribing clinicians should be prepared to advocate for coverage by documenting the medical necessity of weight management as part of diabetes care.

Comparing Wegovy with Other GLP-1–Based Therapies

Wegovy is not the only GLP-1 receptor agonist on the market, but its 2.4 mg weekly dose is specifically optimized for weight loss. Here is how it compares with other agents:

  • Ozempic (semaglutide 0.5 mg, 1.0 mg, and 2.0 mg): Approved for type 2 diabetes and cardiovascular risk reduction. The doses are lower than Wegovy, and weight loss is a secondary benefit. Mean weight loss in clinical trials was 3–6 percent, less than the 9–10 percent seen with Wegovy.
  • Rybelsus (oral semaglutide 7 mg or 14 mg): The only oral GLP-1 receptor agonist. It is approved for type 2 diabetes but not for weight management. Weight loss is modest (2–4 percent).
  • Saxenda (liraglutide 3.0 mg): Approved for weight management in obesity and overweight with comorbidities. Requires daily injections. Mean weight loss in diabetes patients is about 4–5 percent, roughly half of what Wegovy achieves.
  • Mounjaro (tirzepatide): A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes. In the SURMOUNT-1 trial, tirzepatide produced average weight loss of 15–20 percent, exceeding Wegovy. However, tirzepatide is not yet approved for weight management in diabetes (as of early 2023), though regulatory applications are pending. Mounjaro is a potential future competitor.

Wegovy’s advantage lies in its strong evidence base for weight loss specifically in the diabetes population, its once-weekly dosing convenience, and its established safety profile. However, as newer agents like tirzepatide and retatrutide enter the market, the therapeutic landscape will become increasingly competitive.

Potential Benefits Beyond Weight and Glucose Control

Emerging data suggest that semaglutide may offer cardiovascular and renal benefits beyond its effects on weight and glucose. The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) reported in 2023 that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 20 percent in patients with established cardiovascular disease and overweight or obesity without diabetes. While SELECT did not specifically enroll diabetes patients, the results are considered applicable to the diabetes subgroup by many experts.

In addition, semaglutide has been shown to reduce inflammation markers, improve liver steatosis in nonalcoholic fatty liver disease (NAFLD), and delay the progression of chronic kidney disease. These pleiotropic effects make Wegovy an attractive option for patients with type 2 diabetes, who often have multiple comorbidities.

Safety and Tolerability in the Real World

While clinical trials demonstrate a favorable risk-benefit profile, real-world use of Wegovy has raised concerns about tolerability, particularly during the dose-escalation phase. Up to 40 percent of patients discontinue GLP-1 receptor agonists within the first year, often because of gastrointestinal side effects. Strategies to improve adherence include starting at the lowest dose, instructing patients to take the injection after a meal rather than on an empty stomach, avoiding high-fat meals, and using antiemetic medications if needed. Slow titration—spending four weeks at each dose level before moving up—can also help.

Another emerging concern is the risk of pancreatitis. Although the absolute risk is low, clinicians should be vigilant for symptoms such as severe abdominal pain radiating to the back, and they should discontinue Wegovy if pancreatitis is confirmed. Gallbladder disease, including cholecystitis and cholelithiasis, has also been reported, likely related to rapid weight loss rather than a direct drug effect.

Future Directions and Ongoing Research

The regulatory approval of Wegovy for diabetes-related obesity is not the end of the story. Research continues to explore even higher doses of semaglutide (up to 7.2 mg weekly) in the OASIS trial program. Oral semaglutide in higher doses (25 mg and 50 mg) is also being investigated for weight management. Moreover, combination therapies—such as semaglutide with amylin analogs (cagrilintide) or with GIP receptor agonists—are in clinical development and promise even greater weight loss.

For the diabetes population specifically, ongoing studies are examining the use of Wegovy in adolescents with type 2 diabetes, in patients with type 1 diabetes and obesity, and in those with prediabetes. The long-term durability of weight loss and glycemic control beyond two years remains an important question; follow-up data from extension studies will help inform chronic management strategies.

Conclusion

The regulatory approval of Wegovy for diabetes-related obesity marks a landmark moment in the treatment of two closely linked chronic conditions. By leveraging the potent GLP-1–based mechanism of semaglutide, clinicians can now offer patients significant weight loss improvements and glycemic control that were previously unattainable with lifestyle modification alone. The rigorous clinical trial data, reviewed and approved by FDA, EMA, and other global regulatory bodies, provide confidence in the drug’s efficacy and safety profile when used appropriately.

Nevertheless, challenges remain: drug costs, insurance barriers, side-effect management, and the need for intensive lifestyle support must all be addressed for widespread adoption. As the field of obesity pharmacotherapy continues to evolve with new agents and combinations, Wegovy sets a high bar for future treatments. For patients living with the dual burden of diabetes and obesity, this expanded approval offers a realistic path toward better health and improved quality of life.

External Links: